医院获得性感染市场规模、份额和成长分析（按类型、治疗方法、感染类型、最终用户和地区划分）—2026-2033年产业预测

预计到 2024 年，全球医院感染市场规模将达到 308.6 亿美元，到 2025 年将达到 313.2 亿美元，到 2033 年将达到 352.8 亿美元，预测期（2026-2033 年）的复合年增长率为 1.5%。

医院感染市场的发展主要受微生物（如病毒、细菌、真菌和寄生虫）传播的驱动，这些微生物可导致多种感染疾病，包括呼吸系统疾病、消化器官系统和皮肤疾病。这些感染疾病的传播通常透过病患、医护人员和医疗设备之间的交叉感染发生。各种产品和服务，包括灭菌消毒液、防护屏障和内视镜再处理工具，对于控制这些感染疾病至关重要。推动市场成长的因素包括：人们对医院感染的认识不断提高、降低交叉感染率的需求、感染疾病病例的增加以及政府为支持感染控製而采取的倡议。此外，严格的感染预防通讯协定的实施和先进监测技术的应用也显着促进了市场扩张。

全球医院感染市场驱动因素

全球外科手术数量的不断增长推动了对各种手术器械和医疗设备的需求。造成这一增长的因素包括肥胖率上升、文明病增加、人口老化以及脊柱和运动相关损伤的急剧增加。因此，随着这些手术的日益普及，消毒器械和医疗设备的需求也随之增长。人们对医疗环境中消毒和感染控制重要性的认识不断提高，进一步推动了对医院感染相关服务的需求。这一趋势凸显了在医疗机构中维持高卫生标准的重要性。

限制全球医院感染控制市场的因素

可重复使用医疗设备的再处理虽然能为医疗机构带来经济效益并减少废弃物，但也引发了人们对安全性和有效性的重大担忧。例如，手术钳、内视镜和听诊器等器械，如果清洁和消毒不当，可能会残留血液和组织，增加病患手术部位感染（SSI）的风险。这些生物残留物的存在可能使有害微生物在后续消毒程序中存活下来，进而导致医院获得性感染（HAI）。此外，再处理过程中残留的化学物质会刺激组织，进一步增加患者照护的难度。因此，这些问题阻碍了医院管理者和临床医师广泛接受器械再处理的做法。

全球医院感染市场趋势

全球医院感染控制市场正经历显着成长，其主要驱动因素是环境污染和不健康的生活方式等因素导致糖尿病、心血管疾病和癌症等慢性疾病发生率不断上升。随着这些疾病盛行率的持续攀升，手术频率预计也将增加，这必然会提高医院感染的风险。因此，医疗机构对有效的感染控制设备和消毒方法的需求日益增长。这一趋势凸显了开发先进解决方案以减少感染传播的必要性，最终推动了医院感染控制产品和技术市场的发展。

目录

介绍

• 调查目标
• 调查范围
• 定义

调查方法

• 资讯收集
• 二手资料和一手资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分市场机会分析

市场动态与展望

• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特分析

关键市场考察

• 关键成功因素
• 竞争程度
• 关键投资机会
• 市场生态系统
• 市场吸引力指数（2025）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析

全球医院感染市场规模（按类型和复合年增长率划分）（2026-2033 年）

• 装置
  • 消毒器
  • 消毒设备
• 消耗品
  • 消毒剂
  • 无菌耗材
  • 其他的
• 服务

全球医院感染市场规模（依治疗方法及复合年增长率划分）（2026-2033 年）

• 抗菌剂
• 抗病毒药物
• 抗真菌剂
• 其他的

全球医院感染市场规模（按感染疾病类型和复合年增长率划分）（2026-2033 年）

• 血液感染疾病
• 人工呼吸器相关性肺炎（VAP）
• 尿道感染
• 手术部位感染
• 胃肠道感染疾病
• 其他的

全球医院感染市场规模（按最终用户和复合年增长率划分）（2026-2033 年）

• 医院和诊所
• 门诊手术中心
• 其他的

全球医院感染市场规模及复合年增长率（2026-2033）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 亚太其他地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业的市场定位（2025 年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市占率分析（2025 年）
• 主要企业公司简介
  • 公司详情
  • 产品系列分析
  • 依业务板块进行公司股票分析
  • 2023-2025年营收年比比较

主要企业简介

• STERIS plc（Ireland）
• Getinge AB（Sweden）
• 3M（USA）
• Ecolab Inc.（USA）
• Diversey Holdings, Ltd.（USA）
• Roche Holding AG（Switzerland）
• Abbott Laboratories（USA）
• bioMerieux SA（France）
• Thermo Fisher Scientific Inc.（USA）
• Becton, Dickinson and Company（BD）（USA）
• Pfizer Inc.（USA）
• Merck & Co., Inc.（USA）
• Novartis AG（Switzerland）
• GlaxoSmithKline plc（UK）
• Sanofi SA（France）
• Medtronic plc（Ireland）
• Cardinal Health（USA）
• Johnson & Johnson（USA）

结论与建议

Global Hospital-Acquired Infections Market size was valued at USD 30.86 Billion in 2024 and is poised to grow from USD 31.32 Billion in 2025 to USD 35.28 Billion by 2033, growing at a CAGR of 1.5% during the forecast period (2026-2033).

The hospital-acquired infections market is driven by the prevalence of microorganisms, such as viruses, bacteria, fungi, and parasites, which can lead to numerous infections, including respiratory, gastrointestinal, and skin-related conditions. The transmission of these infections often occurs through cross-contamination from patients, healthcare staff, and medical equipment. A variety of products and services, including sterilization, disinfection solutions, protective barriers, and endoscope reprocessing tools, are crucial for managing these infections. Factors propelling market growth include heightened awareness of hospital-acquired infections, the imperative to minimize cross-infection rates, rising cases of infectious diseases, and government initiatives supporting infection control measures. Additionally, the adoption of stringent infection prevention protocols and the integration of advanced monitoring technologies contribute significantly to market expansion.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Hospital-Acquired Infections market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Hospital-Acquired Infections Market Segments Analysis

Global Hospital-Acquired Infections Market is segmented by Type, Treatment, Infection Type, End User and region. Based on Type, the market is segmented into Equipment, Consumables and Services. Based on Treatment, the market is segmented into Antibacterial, Antiviral, Antifungal and Others. Based on Infection Type, the market is segmented into Bloodstream Infections, Ventilator-Associated Pneumonia (VAP), Urinary Tract Infection, Surgical-Site Infection, Gastrointestinal Infections and Others. Based on End User, the market is segmented into Hospitals & Clinics, Ambulatory Surgical Centers and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Hospital-Acquired Infections Market

The rising prevalence of surgical procedures globally has led to an increased need for various surgical instruments and medical devices. Factors contributing to this rise include the growing rates of obesity, lifestyle-related illnesses, an aging demographic, and a surge in spine and sports-related injuries. Consequently, as these procedures become more common, the demand for sterilized equipment and medical devices intensifies. Enhanced awareness regarding the importance of sterilization and infection control in healthcare environments is further driving the demand for services related to hospital-acquired infections. This trend underscores the critical nature of maintaining high standards of hygiene in medical settings.

Restraints in the Global Hospital-Acquired Infections Market

The reprocessing of reusable medical devices presents both financial benefits and waste reduction for healthcare providers but also raises significant safety and efficacy concerns. Devices such as surgical forceps, endoscopes, and stethoscopes may harbor residual blood and tissue if not properly cleaned and sterilized, thereby elevating the risk of surgical site infections (SSIs) in patients. The presence of this biological debris can allow harmful microorganisms to survive through subsequent disinfection attempts, potentially resulting in hospital-acquired infections (HAIs). Additionally, residual chemicals from reprocessing can irritate tissue, further complicating patient care. Consequently, these issues hinder the widespread acceptance of reprocessing practices among hospital administrators and clinicians.

Market Trends of the Global Hospital-Acquired Infections Market

The Global Hospital-Acquired Infections market is experiencing significant growth driven by the rising incidence of chronic diseases such as diabetes, cardiovascular disorders, and cancer, largely attributed to factors like environmental pollution and unhealthy lifestyles. As the prevalence of these diseases continues to grow, the frequency of surgical procedures is also expected to increase, inevitably heightening the risk of hospital-acquired infections. Consequently, there is a greater demand for effective infection control devices and sterilization methods within healthcare facilities. This trend underscores the necessity for advanced solutions to mitigate infection transmission, ultimately propelling the market for hospital-acquired infection control products and technologies forward.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Hospital-Acquired Infections Market Size by Type & CAGR (2026-2033)

• Market Overview
• Equipment
  • Sterilization Equipment
  • Disinfection Equipment
• Consumables
  • Disinfectants
  • Sterilization Consumables
  • Others
• Services

Global Hospital-Acquired Infections Market Size by Treatment & CAGR (2026-2033)

• Market Overview
• Antibacterial
• Antiviral
• Antifungal
• Others

Global Hospital-Acquired Infections Market Size by Infection Type & CAGR (2026-2033)

• Market Overview
• Bloodstream Infections
• Ventilator-Associated Pneumonia (VAP)
• Urinary Tract Infection
• Surgical-Site Infection
• Gastrointestinal Infections
• Others

Global Hospital-Acquired Infections Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals & Clinics
• Ambulatory Surgical Centers
• Others

Global Hospital-Acquired Infections Market Size & CAGR (2026-2033)

• North America (Type, Treatment, Infection Type, End User)
  • US
  • Canada
• Europe (Type, Treatment, Infection Type, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Treatment, Infection Type, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Treatment, Infection Type, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Treatment, Infection Type, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• STERIS plc (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Getinge AB (Sweden)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• 3M (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ecolab Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Diversey Holdings, Ltd. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche Holding AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• bioMerieux S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Becton, Dickinson and Company (BD) (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Medtronic plc (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cardinal Health (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations